The Swiss biotech company, EraCal Therapeutics, has developed an in-vivo screening platform to create drugs that target metabolic syndrome. Their drugs include appetite-suppressors that are selective to food intake, without side-effects and outperform current anti-obesity agents in both potency and selectivity. This allows patients to suppress their appetite and lose weight, providing a new solution to the global obesity epidemic.